Actively Recruiting
Global Observational Study of Adults With Transthyretin-Mediated Amyloidosis With Cardiomyopathy Treated With Vutrisiran in Real-World Settings
Led by Alnylam Pharmaceuticals · Updated on 2026-10-09
2000
Participants Needed
27
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to understand adult patients with transthyretin-mediated amyloidosis with cardiomyopathy ATTR-CM who are treated with vutrisiran in everyday medical care. The study describes patients clinical characteristics, treatment approaches, quality of life, and healthcare usage while comparing the long-term effects of vutrisiran with other approved treatments for ATTR-CM. Participants diagnosed with ATTR-CM and starting treatment with vutrisiran or other approved therapies will be observed. The study is observational and does not involve administering treatments but follows patients receiving routine care. Patients will be tracked for up to five years, including monitoring treatment patterns and patient experiences. During the study, participants will be regularly assessed for heart function using the New York Heart Association NYHA classification and other patient-reported measures such as quality of life questionnaires and treatment satisfaction surveys. Data will be collected from enrollment until five years or until withdrawal, loss to follow-up, or death, whichever occurs first. This long-term observation helps evaluate real-world treatment outcomes and patient health over time.
CONDITIONS
Brief Title
DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting
Research Team
C
Clinical Trial Information Line
C
Clinical Trial Information Line
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here